Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

105.75 -1.84 (-1.71%)
Streaming Delayed Price Updated: 9:52 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 455,812
Open 106.71
Bid (Size) 105.74 (3)
Ask (Size) 105.76 (4)
Prev. Close 107.59
Today's Range 105.70 - 106.75
52wk Range 89.67 - 121.64
Shares Outstanding 1,750,942,289
Dividend Yield 1.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
It's not just enough for a company to pay a dividend, investors should look for dividend growth stocks that can continue to pay. 
Via InvestorPlace
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more. 
Via InvestorPlace

Performance

YTD
-3.73%
-3.73%
1 Month
-3.87%
-3.87%
3 Month
-7.24%
-7.24%
6 Month
+11.54%
+11.54%
1 Year
-4.21%
-4.21%

More News

Read More
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Via Benzinga
Abbott Laboratories Dividend Stock Analysis
Via Talk Markets
Abbott Laboratories Unusual Options Activity
Via Benzinga
Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?
Via Benzinga
Topics Bonds
Exposures Debt Markets
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
ABT Stock Earnings: Abbott Laboratories Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Abbott Laboratories Outlook is Healthy: Buy the Dip
Via MarketBeat
Exposures COVID-19
Abbott Beats Q1 Expectations With $10 Billion In Sales, $0.98 EPS
Via Talk Markets
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Abbott Undercuts Its 200-Day Line And A Flat Base Despite Its 'Solid' Quarterly Report
Via Investor's Business Daily
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance
Via Benzinga
Wall Street Poised To Rebound From Slump As Earnings Optimism Grows: Analyst Eyes This S&P 500 Level As Attractive Entry Point
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For April 17, 2024
Via Benzinga
Investor Optimism Decreases; Dow Ends 6-Session Losing Streak
Via Benzinga
Topics Stocks
Exposures US Equities
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Johnson & Johnson is as Cheap as it’s Going to Get
Via MarketBeat
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
3 Buy Rated Stocks To Consider As Earnings Approach
Via Talk Markets
Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer
Via Benzinga
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
Via The Motley Fool
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.